Investigation of intracellular signals generated by γ-interferon and IL-4 leading to the induction of class II antigen expression by S. Vassiliadis, N. Kyrpides, D. Stravopodis, M. Grigoriou, I. Athanassakis, J. Papamatheakis

“…This study shows that the immunologically important class II antigens in human cells are up-regulated predominately via the same pathway after gamma-interferon (γ-IFN) treatment, whereas murine cells are activated by other signalling routes. …”
Get full text

Optimized production and antiviral activity evaluation of recombinant chicken interferon-alpha using an improved Baculovirus expression system by Yuxia Zhang, Wenwen Dong, Feng Li, Kai Meng, Guiming Li, Xiaoyuan Yuan

“…Chicken interferon-alpha (chIFN-α) reportedly has good inhibitory activity against various pathogens. …”
Get full text

Regulation of interferon alpha production by the MAGUK-family protein CASK under H5N1 infection by Jing-Ying Huang, Jing-Ying Huang, Pei-Shan Sung, Shie-Liang Hsieh, Shie-Liang Hsieh, Shie-Liang Hsieh, Shie-Liang Hsieh

Subjects: Get full text

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation by B. Uz, O. Bektas, E. Eliacik, H. Goker, Y. Erbilgin, M. Sayitoglu, N. Sayinalp, S. Aksu, Y. Buyukasik, O. Ozcebe, I. C. Haznedaroglu

“…The aim of this paper is to report a patient with complicated CML resistant to treatment and progressed despite the administration of bosutinib, imatinib mesylate, nilotinib, dasatinib, interferon alpha 2a, cytotoxic chemotherapy, and allogeneic hematopoietic stem cell transplantation. …”
Get full text

Combination of Enrichment Using Gene Ontology and Transcriptomic Analysis Revealed Contribution of Interferon Signaling to Severity of COVID-19 by Hilmi Farhan Ramadhani, Annisa Annisa, Aryo Tedjo, Dimas R. Noor, Wisnu Ananta Kusuma

“…A combination of enrichment using GOs and transcriptomic analysis showed that hyperinflammation and severity of COVID-19 may be caused by interferon signaling.…”
Get full text

Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. by Aldina Mesic, Emahlea K Jackson, Mathias Lalika, David M Koelle, Rena C Patel

“…The interferon (IFN) system is a potent line of defense against viral infections. …”
Get full text

Identification of ALEKSIN as a novel multi-IRF inhibitor of IRF- and STAT-mediated transcription in vascular inflammation and atherosclerosis by Aleksandra Antonczyk, Katarzyna Kluzek, Natalia Herbich, Mahdi Eskandarian Boroujeni, Bart Krist, Dorota Wronka, Anna Karlik, Lukasz Przybyl, Adam Plewinski, Joanna Wesoly, Hans A. R. Bluyssen

Subjects: “…interferon regulatory factor…”
Get full text

Contemporary Treatment Practices for Subacute Sclerosing Panencephalitis: A Nationwide Survey Among Adult and Pediatric Neurologists in India by Divyani Garg, Archita Makharia, Ayush Agarwal, Ajay Garg, Achal K Srivastava

Subjects: “…interferon…”
Get full text

Sarcoid-like reaction at the patient with chronic hepatitis C on a background of antiviral therapy by A. V. Lapshin, N. I. Kokina, M. V. Mayevskaya, I. A. Sokolina, V. T. Ivashkin

Subjects: Get full text

Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. by Shridhar Bale, Jean-Philippe Julien, Zachary A Bornholdt, Christopher R Kimberlin, Peter Halfmann, Michelle A Zandonatti, John Kunert, Gerard J A Kroon, Yoshihiro Kawaoka, Ian J MacRae, Ian A Wilson, Erica Ollmann Saphire

“…The C-terminal double-stranded (ds)RNA-binding domain (RBD) of VP35 has been implicated in interferon antagonism and immune evasion. Crystal structures of the VP35 RBD from two ebolaviruses have previously demonstrated that the viral protein caps the ends of dsRNA. …”
Get full text

Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis by Loïs Bolko, Loïs Bolko, Loïs Bolko, Céline Anquetil, Céline Anquetil, Alba Llibre, Solène Maillard, Damien Amelin, Karim Dorgham, Vincent Bondet, Océane Landon-Cardinal, Océane Landon-Cardinal, Océane Landon-Cardinal, Ségolène Toquet, Ségolène Toquet, Kuberaka Mariampillai, Samuel Malatre, Alexandrine Mahoudeau, Baptiste Hervier, Mathieu Rodero, Guy Gorochov, Darragh Duffy, Olivier Benveniste, Olivier Benveniste, Yves Allenbach, Yves Allenbach

Subjects: “…interferon…”
Get full text

HIV and diabetes impair M. tuberculosis-specific interferon-gamma responses on QuantiFERON-TB Gold Plus testing by J.S. Zifodya, J.S. Kreniske, T.M. Temu, S.J. Masyuko, E.F. Attia, J.N. Mogaka, D. Onyango, S.T. Page, K. Crothers, J. Kinuthia, C. Farquhar, S.M. LaCourse

Subjects: Get full text

Killer-Cell Inhibitory Receptors, CD158a/b, are Upregulated by Interleukin-2, but not Interferon-γ or Interleukin-4 by Toshiaki Kogure, Hiroshi Fujinaga, Atsushi Niizawa, Le Xuan Hai, Yutaka Shimada, Hiroshi Ochiai, Katsutoshi Terasawa

“…Therefore, we investigated the regulation of expression of representative KIRs, CD158a and CD158b, by cytokines such as interleukin-2 (IL-2), IL-4 and interferon-γ (IFN-γ). Neither IL-4 nor IFN-γ affected the expression of CD158a/b, but incubation for 48 h with IL-2, which enhances the killer activity of NK cells, upregulated the expression of the KIRs. …”
Get full text

Evolución clínica de pacientes con esclerosis múltiple remitente- recurrente tratados con interferón beta-1a by Lazaro Aurelio Vazquez-Gomez, Carlos Hidalgo Mesa, Yunier Broche Pérez

Subjects: Get full text

Blocking Type I Interferon Production: A New Therapeutic Option to Reduce the HIV-1-Induced Immune Activation by Moritz Ries, Kathrin Pritschet, Barbara Schmidt

“…An important cause appears to be the HIV-1-induced chronic immune activation, propagated by inappropriate release of proinflammatory cytokines and type I interferons. This immune dysregulation can be reduced in vitro by inhibitors blocking the endosomal acidification. …”
Get full text

A zebrafish model of Ifih1-driven Aicardi–Goutières syndrome reproduces the interferon signature and the exacerbated inflammation of patients by Beatriz Bernal-Bermúdez, Beatriz Bernal-Bermúdez, Beatriz Bernal-Bermúdez, Alicia Martínez-López, Alicia Martínez-López, Francisco J. Martínez-Morcillo, Francisco J. Martínez-Morcillo, Francisco J. Martínez-Morcillo, Sylwia D. Tyrkalska, Sylwia D. Tyrkalska, Sylwia D. Tyrkalska, Teresa Martínez-Menchón, Teresa Martínez-Menchón, Teresa Martínez-Menchón, Pablo Mesa-del-Castillo, Pablo Mesa-del-Castillo, Pablo Mesa-del-Castillo, María L. Cayuela, María L. Cayuela, María L. Cayuela, Victoriano Mulero, Victoriano Mulero, Victoriano Mulero, Diana García-Moreno, Diana García-Moreno

“…Type I interferonopathies are a heterogenic group of rare diseases associated with an increase in type I interferon (IFN). The main challenge for the study of Type I interferonopathies is the lack of a well-founded animal model to better characterize the phenotype as well as to perform fast and large drug screenings to offer the best treatment options. …”
Get full text

A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C by Masafumi Komatsu, Tsuyoshi Ono, Ko Nakajima, Itaru Toyoshima, Mitsuro Chiba, Osamu Masamune, Shunji Ohkubo, Tsukasa Yoshida, Hitoshi Yagisawa, Kanji Komatsu, Hideki Wakamatsu, Nobuo Yamada, Hiroyuki Watanabe, Tsuyoshi Mukojima, Mitsuo Goto

“…Sixty-one chronic hepatitis C patients were randomly assigned to receive either 6x106 or 9x106 U of recombinant interferon-alpha-2a (IFNα-2a) six days a week for the first two weeks of treatment, followed in both cases by 6x106 U three days a week for the next 22 weeks. …”
Get full text

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy by Dorota Zarębska-Michaluk, Iwona Buczyńska, Krzysztof Simon, Magdalena Tudrujek-Zdunek, Ewa Janczewska, Dorota Dybowska, Marek Sitko, Beata Dobracka, Jerzy Jaroszewicz, Paweł Pabjan, Jakub Klapaczyński, Łukasz Laurans, Włodzimierz Mazur, Łukasz Socha, Olga Tronina, Miłosz Parczewski, Robert Flisiak

“…The development of interferon- (IFN-) free regimens substantially improved efficacy of treatment for HCV, but despite excellent effectiveness the failures still occur. …”
Get full text

Interferon-Gamma Release Assays for Screening of Health Care Workers in Low Tuberculosis Incidence Settings: Dynamic Patterns and Interpretational Challenges by Madhukar Pai, Kevin Elwood

Get full text

Corrigendum: A zebrafish model of Ifih1-driven Aicardi–Goutières syndrome reproduces the interferon signature and the exacerbated inflammation of patients by Beatriz Bernal-Bermúdez, Beatriz Bernal-Bermúdez, Beatriz Bernal-Bermúdez, Alicia Martínez-López, Alicia Martínez-López, Francisco J. Martínez-Morcillo, Francisco J. Martínez-Morcillo, Francisco J. Martínez-Morcillo, Sylwia D. Tyrkalska, Sylwia D. Tyrkalska, Sylwia D. Tyrkalska, Teresa Martínez-Menchón, Teresa Martínez-Menchón, Teresa Martínez-Menchón, Pablo Mesa-del-Castillo, Pablo Mesa-del-Castillo, Pablo Mesa-del-Castillo, María L. Cayuela, María L. Cayuela, María L. Cayuela, Victoriano Mulero, Victoriano Mulero, Victoriano Mulero, Diana García-Moreno, Diana García-Moreno

Get full text